secwatch.observer — SEC 8-K summary
======================================

Issuer:     Incannex Healthcare Inc. (IXHL)
CIK:        0001873875
Form:       8-K
Filed at:   2025-04-03T23:59:59+00:00
Accession:  0001213900-25-028373
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incannex completes Phase 2 enrollment in RePOSA trial of IHL-42X for OSA; topline data expected H1 2025
--------------------------------------------------------------------------------

- Completed enrollment of >120 patients across 11 U.S. sites in Phase 2 dose-finding portion of RePOSA Phase 2/3 study of IHL-42X for OSA.
- Topline Phase 2 clinical data expected in first half 2025; results will determine optimal dose for Phase 3.
- Phase 3 expansion planned with ~440 patients across four treatment arms over 52 weeks to support future FDA NDA submission.
- IHL-42X is an oral fixed-dose combination of dronabinol and acetazolamide targeting physiological pathways of OSA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873875/000121390025028373/0001213900-25-028373-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873875/000121390025028373/ea0237061-8k_incannex.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-028373

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer